Clinical trial
A Study to Determine the Degree of Additional Reduction in CV Risk in Lowering…
NCT00327691 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00327691 |
|---|---|
| Title | A Study to Determine the Degree of Additional Reduction in CV Risk in Lowering LDL Below Minimum Target Levels |
| Official title | The Effect Of LDL-Cholesterol, Lowering Beyond Currently Recommended Minimum Targets On Coronary Heart Disesse (CHD) Recurrence In Patients With Pre-Existing CHD |
| Acronym | TNT |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Cardiovascular Disease, Cerebrovascular Accident, Coronary Heart Disease |
| Intervention type | Drug |
| Interventions | Atorvastatin |
| Enrollment | 8,600 |
| Start date | Apr 1, 1998 |
| Completion | Aug 1, 2004 |
| First posted | May 18, 2006 |
| Last update posted | May 3, 2007 |
| Countries | Australia, Austria, Belgium, Canada, France, Germany, Ireland, Italy, Netherlands, South Africa, Spain, Switzerland and 2 more |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: